Relapse following allogeneic transplant, autologous transplant and chemotherapy.
| . | Allogeneic transplant . | Autologous transplant . | ChemoStudy therapy . |
|---|---|---|---|
| * Data for children excluded. In the MRC study, BMT was compared with an observation arm after 4 cycles of chemotherapy, rather than a direct comparison with high-dose chemotherapy as in the other studies. | |||
| Abbreviations: See Table 3; GIMEMA, Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto | |||
| GIMEMA, 199528 | 24% | 40% | 57% |
| GOELAM, 199724 | 28% | 45% | 55% |
| *MRC, 199825 | 19% | 35% | 53% |
| ECOG/SWOG, 199826 | 29% | 48% | 61% |
| . | Allogeneic transplant . | Autologous transplant . | ChemoStudy therapy . |
|---|---|---|---|
| * Data for children excluded. In the MRC study, BMT was compared with an observation arm after 4 cycles of chemotherapy, rather than a direct comparison with high-dose chemotherapy as in the other studies. | |||
| Abbreviations: See Table 3; GIMEMA, Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto | |||
| GIMEMA, 199528 | 24% | 40% | 57% |
| GOELAM, 199724 | 28% | 45% | 55% |
| *MRC, 199825 | 19% | 35% | 53% |
| ECOG/SWOG, 199826 | 29% | 48% | 61% |